LogicBio Therapeutics Inc expected to post a loss of 34  cents a share - Earnings Preview

ContextLogic Holdings

04/03/2022 12:02

* LogicBio Therapeutics Inc  LOGC.OQ   LOGC.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 7
(estimated). 
    * The Lexington Massachusetts-based  company is expected to
report
 a 167.5% increase in revenue to $1.45 million from $542
thousand a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for LogicBio
Therapeutics Inc
is for a loss of 34 cents per share. For the same quarter last
year, the company reported a loss of 22 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for LogicBio
Therapeutics Inc is $7​, about 90.4% above​ its last closing
price of $0.67. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.34       -0.30      -0.31     Missed  -4.5
 Jun. 30 2021  -0.28       -0.24      -0.33     Missed  -39.4
 Mar. 31 2021  -0.25       -0.25      -0.32     Missed  -25.5​
 Dec. 31 2020  -0.32       -0.32      -0.22     Beat    32.3
 ​​Sep.        -0.40       -0.41      -0.34     Beat    17.6
 30 2020                                                
 Jun. 30 2020  -0.51       -0.48      -0.35     Beat    27.1​
 Mar. 31 2020  -0.48       -0.48      -0.41     Beat    14.2
 Dec. 31 2019  -0.44       -0.49      -0.51     Missed  -3.2
 This summary was machine generated March 4 at 12:02 GMT.  All
figures in US dollars  unless otherwise stated